NYSE$BMY

Bristol-Myers Squibb Co · Q2 2026 earnings

Q2 2026 earnings · · Before market open · Investor relations

Briefing

Bristol-Myers Squibb reported second quarter 2026 revenues of $13.0 billion, up 6%, with GAAP EPS of $1.62 and non-GAAP EPS of $2.04.

Bristol-Myers Squibb delivered strong Q2 2026 results driven by 15% growth in the Growth Portfolio to $7.6 billion. The company raised full-year 2026 revenue guidance to $49.0-$50.0 billion and non-GAAP EPS to $6.75-$7.00. Net income attributable to BMS reached $3.3 billion.

  • Total revenues rose 6% to $12.973 billion, with Growth Portfolio up 15% to $7.56 billion.
  • GAAP EPS increased 153% to $1.62 and non-GAAP EPS rose 40% to $2.04.
  • U.S. revenues grew 6% to $8.991 billion and international revenues grew 6% to $3.982 billion.
  • Full-year outlook raised with revenue guidance now $49.0-$50.0 billion and non-GAAP EPS $6.75-$7.00.

Headline financials

Total Revenue

$13B

Previous: $12.3B+5.7%
EPS (adj)

$2.04

Previous: $0.64+218.8%
Gross Margin

71.3%

No prior period
GAAP Effective Tax Rate

18.8%

No prior period
Net Income

$3.32B

Previous: $1.31B+153.2%
Gross Profit

$9.25B

Previous: $8.9B+3.9%
Cash & Equivalents

$8.72B

Previous: $12.6B-30.8%

Revenue & EPS history

Bristol-Myers Squibb · Revenue · Quarterly

$13B

Q2 2026+5.7%vs Q2 2025
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Bristol-Myers Squibb · $13B total across 2 segments · Q2 2026

  • Growth Portfolio
    $7.56B
  • Legacy Portfolio
    $5.42B

Forward guidance

Company raised 2026 full-year non-GAAP revenue guidance to approximately $49.0 billion to $50.0 billion and non-GAAP EPS to $6.75 to $7.00.

Tailwinds

  • Broad-based momentum across the portfolio
  • Growth Portfolio continues to deliver strong results
  • Eliquis worldwide revenue growth raised to 20%-25%

Headwinds

  • Operating expenses increased to approximately $16.5 billion

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

-0.1%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+0.9%

Avg return

30 days after

47%

34 / 73 earnings

Positive

+8.2%

Q2 2024

Best reaction

-9.9%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026-0.9%-1.1%-0.7%
Q4 2025+3.3%+5.6%+4.6%
Q3 2025+7.1%+7.0%+15.5%
Q2 2025-5.8%-0.3%+2.6%
Q1 2025+0.4%+1.4%-3.5%
Q4 2024-3.8%-6.3%+2.3%
Q3 2024+3.2%+6.2%+12.5%
Q2 2024+8.2%+5.1%+6.3%
Q1 2024-8.2%-10.1%-15.6%
Q4 2023-1.4%-0.1%+4.6%
Q3 2023-9.9%-9.0%-12.1%
Q2 2023-3.2%-3.0%-2.1%
Q1 2023-1.8%+0.1%-6.2%
Q4 2022+4.5%+4.6%-2.7%
Q3 2022+2.0%+5.3%+8.4%
Q2 2022+1.5%-0.0%-3.3%
Q1 2022-2.7%-1.2%-1.4%
Q4 2021+3.3%+4.8%+8.3%
Q3 2021-1.9%+0.8%-2.9%
Q2 2021+1.0%+0.8%-1.3%
Q1 2021-5.5%-3.2%-0.5%
Q4 2020-1.8%-3.7%-2.6%
Q3 2020-2.5%-1.4%-4.8%
Q2 2020+2.2%+5.8%+0.4%
Q1 2020-0.1%+3.6%+0.3%
Q4 2019+1.0%+2.1%-8.1%
Q3 2019+0.5%-0.8%+0.1%
Q2 2019+5.0%+3.1%+7.7%
Q1 2019+2.8%+4.1%+4.9%
Q4 2018-2.1%-3.3%+2.0%
Q3 2018+3.3%+2.4%+8.4%
Q2 2018-3.6%-0.5%+1.6%
Q1 2018+1.0%+1.8%+2.0%
Q4 2017-4.1%-1.2%+4.1%
Q3 2017-6.3%-3.7%-4.0%
Q2 2017-1.3%+0.2%+4.3%
Q1 2017+4.2%+4.1%+0.4%
Q4 2016-3.7%-0.8%+13.9%
Q3 2016+3.5%+3.1%+15.6%
Q2 2016-2.2%-1.9%-23.1%
Q1 2016+2.8%
Q4 2015+0.7%
Q3 2015+4.7%
Q2 2015-4.9%
Q1 2015-1.3%
Q4 2014-1.8%
Q3 2014+2.0%
Q2 2014+0.1%
Q1 2014-0.5%
Q4 2013-7.8%
Q3 2013-0.7%
Q2 2013-0.8%
Q1 2013-2.8%
Q4 2012+5.1%
Q3 2012+1.5%
Q2 2012+3.1%
Q1 2012-0.6%
Q4 2011+0.9%
Q3 2011-1.3%
Q2 2011+0.2%
Q1 2011-0.0%
Q4 2007-1.5%
Q4 2010-1.5%
Q3 2010-1.1%
Q2 2010-0.4%
Q1 2009+4.0%
Q1 2010+0.7%
Q4 2009-0.6%
Q3 2009-2.0%
Q3 2008-2.0%
Q2 2009+5.5%
Q4 2008+5.5%
Q2 2008+5.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro